Cancer is the most common cause of death and the rate of occurrence is increasing steadily. Tumor heterogeneity presents a major problem in the management of the disease and normal anticorps further impair the progression of disease. With the advent of mAbs, the progression-free and cumulative survival of cancer patients has increased considerably. But little has been done to harness other antibody isotypes than IgG. The use of mAbs is not enough. To strengthen these therapies, ‘next-generation antibodies’ were created by enhancing a particular function of classical antibodies and forming a group of highly efficient and accurate therapy compounds. Advanced antibody-related approaches include antimicrobial conjugates, FC-engineered antibodies, fragments of anticorps, radio-immunotherapy compounds, bispecific anticuerpos and alternate immunoglobulin (non-IgG), especially IgE. The current study outlines various approaches to meeting the needs of next-generation antibody therapies. Careful evaluation of the best-suited innovation approach is critical in designing customised, more specific, and more effective anti-cancer mAbs to increase cancer patient outcomes. The study illustrates the substantial evidence for IgE using an extremely cytotoxic effector arm as a possible next-generation anticancer immunotherapy.
Precision medicine in clinical oncology: the journey from IgG antibody to IgE
